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Introduction: Thyroid cancer is a rare disease with an incidence of around 37,000 cases per 
year. However, its incidence is rising faster than many other cancers and for men this disease 
ranks highest overall in the rate of increase (2.4% annual increase) in cancer deaths. As the 
number of radioactive iodine-resistant thyroid cancers increases, the need for newer treatments 
has become more important. Axitinib is one of many new small molecule inhibitors of growth 
factor receptors that have shown promise in the treatment of many cancers. It targets the vascular 
endothelial growth factor receptors 1, 2 and 3.
Aims: The goal of this article is to review the published evidence for the use of axitinib in the 
treatment of thyroid cancer and define its therapeutic potential.
Evidence review: The major evidence of axitinib activity has appeared in meeting report 
abstracts. One phase II study has been published. This included patients with any histological 
type of thyroid cancer that was not amenable to treatment with radioactive iodine.
Clinical potential: To date, in phase II clinical studies axitinib has demonstrated antitumor 
activity in advanced refractory thyroid cancer. As a monotherapy it resulted in a 30% response 
rate with another 38% of patients having stable disease. Axitinib appears to have a good 
tolerability profile, with hypertension being the most common grade 3 or greater side effect.
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Core evidence proof of concept summary for axitinib in thyroid cancer
Outcome measure Emerging evidence
Efficacy Potential to use as monotherapy at a dose of 5 mg 
twice daily; stable disease achieved in 38% of patients 
and progression-free survival of 18.1 months
response rates Evidence of activity with overall response rates of 30%
Biomarker expression Decreases levels of soluble vEGFr 2 and 3. Blood 
pressure elevation may correlate with response
Tolerability well tolerated, with hypertension, fatigue, and 
proteinuria as the most common grade 3 side effects
Abbreviations: vEGFr, vascular endothelial growth factor receptor.
Scope, aims, and objectives
Thyroid cancer is a relatively rare disease with an incidence of 37,340 cases per year. 
It retains an excellent prognosis with a mortality of only 1,590 per year.1 However, 
its incidence is rising and for men this disease ranks highest overall in the rate of 
increase (2.4% annual increase) in cancer deaths.2 Radioactive iodine continues to be 
the initial treatment for differentiated thyroid cancer with distant metastatic disease Core Evidence 2009:4 44
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and can produce five-year overall survival rates of around 
50%. The more aggressive variants as well as anaplastic and 
medullary subtypes of thyroid cancer however need better 
treatments to improve survival, and many agents have now 
shown some promise in clinical trials.3
Axitinib is an oral, potent, and selective inhibitor of 
vascular endothelial growth factor receptors (VEGFR) 1, 2, 
and 3. Axitinib was more than 10-fold less potent in inhibiting 
platelet-derived growth factor receptor beta (PDGFR) and 
c-KIT in cell-based assays.4 Thyroid cancers have elevated 
levels of VEGF compared with normal controls. Axitinib is 
one of a number of inhibitors of the VEGF pathway being 
studied in the treatment of thyroid cancers. The objective 
of this review is to evaluate the potential role of axitinib in 
the treatment of advanced thyroid cancers. Current options 
for the treatment of thyroid cancer, and the molecular basis 
underlying the use of tyrosine kinase inhibitors, are also 
discussed.
Methods
The English language medical literature was searched for 
relevant articles related to the use of axitinib in advanced 
thyroid cancer. The search terms used were “Axitinib or 
AG-013736,” “thyroid cancer” and the articles published 
covered a period between 1998 to September 2008. The 
following databases were used:
•  PubMed (http://www.ncbi.nlm.nih.gov/entrez)
•  National Cancer Institute (http://www.cancer.gov/)
•  Clinical Evidence (BMJ) (http://www.clinicalevidence.
com/)
•  Clinical Trials (http://www.clinicaltrials.com/)
The annual scientific sessions from the American Society 
of Clinical Oncology (ASCO), European Society of Medical 
Oncology (ESMO), American Association of Cancer 
Research (AACR), and American Thyroid Association 
(ATA; Thyroid) were searched for relevant meeting 
abstracts. A total of 27 articles were identified from those 
represented by systematic review. Articles were excluded 
because they were considered not relevant (Table 1). Two 
papers were identified5,6 replacing or supplementing earlier 
abstracts.
Few studies were identified for axitinib use specifically 
in thyroid cancer, but many references investigated its use 
and safety in the treatment of other malignancies with and 
without chemotherapy.
No health economics publications were found. One 
quality of life publication was found although it was for a 
different disease group.
Disease overview
Thyroid cancer is rare compared with other solid malignancies. 
It is the sixth most common cancer in women with an inci-
dence of about 28,000 cases per year, but in men affects 
less than 10,000 individuals per year in the United States.1 
Although relatively rare, the incidence of thyroid cancer more 
than doubled between 1984 and 2004 in the United States. 
Between 1995 and 2004, thyroid cancer was the third fastest 
growing cancer diagnosis, behind only peritoneum, omen-
tum, and mesentery cancers and “other” digestive cancers. 
Similarly dramatic increases in thyroid cancer incidence have 
also been observed in Canada, Australia, Israel, and several 
European countries.7 The factors underlying this epidemic 
are not well understood, but may be partly a result of better 
screening and diagnosis with fine needle aspirations.8
Thyroid cancers arise from two cell types. The follicular 
cells give rise to the differentiated and undifferentiated types. 
Differentiated thyroid cancers account for 85%–95% of cases 
and consist mainly of papillary and follicular subtypes. The 
poorly and undifferentiated category includes anaplastic 
thyroid carcinoma, paradoxically one of the most aggres-
sive and chemotherapy-resistant tumors known in humans.9 
Parafollicullar or C cells are the cell of origin for medullary 
thyroid carcinoma, which may be familial or sporadic.
The epidemiology of thyroid cancer is unclear in the 
majority of cases but environmental and genetic factors 
are thought to contribute to an increased risk; these include 
environmental goiter, radiation exposure, and, in the case of 
medullary thyroid cancer, autosomal dominant inheritance.8
Differentiated thyroid cancers have an excellent 
prognosis when treated at an early stage and, even in cases 
Table 1 Evidence base included in the review
Category Number of records
Full papers Abstracts
initial search 17 10
records included 15 7
records excluded 2 3
Additional studies identified 2 2
Level 1 clinical evidence 0 0
Level 2 clinical evidence 1 0
Level 3 clinical evidence 14 7
Trials other than rCT 14 7
Case reports 0 0
Economic evidence 1 0
Notes: For definition of levels of evidence, see Core Evidence website (http://www.
dovepress.com/core-evidence-journal).
Abbreviation: rCT, randomized controlled trial.Core Evidence 2009:4 45
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of metastatic disease, patients can live for many years. The 
excellent survival of patients with thyroid cancer as well as 
the relatively low incidence of the disease has meant that 
it is probably not a significant economic burden on health 
care systems, although no published data could be found 
to confirm this. However, the incidence of the disease as 
mentioned is rising faster than almost any other cancer and 
therefore, if more aggressive variants continue to emerge, 
the toll on society is also likely to increase.
Current therapy options
Surgery plus radioactive iodine therapy has remained the 
standard treatment for early and locally advanced differ-
entiated thyroid cancer. Several groups have demonstrated 
a survival advantage in patients treated with a total or 
near-total thyroidectomy followed by radioactive iodine 
treatment. The question of neck dissection is not as clear 
and probably should be reserved for patients with clini-
cally positive nodes.10 Advanced metastatic thyroid cancers 
that are refractory to radioactive iodine have traditionally 
been treated with doxorubicin, platinum agents, taxanes, or 
combinations of the above based on little data.11 Cancers that 
are refractory to radioiodine have a poor prognosis with a 
10-year survival rate of around 15%.12 Currently doxorubicin 
is the only systemic agent approved for the treatment of 
metastatic thyroid cancer. In a randomized trial comparing 
doxorubicin 60 mg/m2 with the same dose of doxorubicin 
plus cisplatin 40 mg/m2 administered every three weeks a 
complete response was achieved in five of 43 patients. There 
was no difference in survival between the arms, but of the 
patients who had a complete response, two had a long-term 
survival.13 This impressive response rate however, was 
unable to be replicated in future studies and it soon became 
clear that new approaches to treatment were needed.
As mentioned earlier, thyroid cancers have elevated levels 
of VEGF compared with normal controls, and this pathway 
has become a target for some of the new small molecule 
inhibitors. VEGF proteins are important mediators of angio-
genesis and it was felt that by inhibiting this pathway either 
with antibodies, inhibitors of the receptor tyrosine kinase or 
downstream proteins, it would be possible to treat resistant 
thyroid cancers. The recent explosion of multitargeted inhibi-
tors in medical oncology has resulted in many of them being 
tested in refractory thyroid cancer. Motesanib (AMG 706) 
is a novel oral inhibitor of VEGF receptors, platelet-derived 
growth factor receptor, and KIT. It was tested in a phase II 
study in 93 patients who had progressive, radioiodine refrac-
tory, differentiated thyroid cancer. The authors noted a 14% 
response rate with 67% of patients achieving stable disease 
(35% for 24 weeks or longer).14 The major side effects appeared 
to be hypertension and fatigue. Although this agent is not yet 
approved for treatment, it also represents a proof of concept 
and should lead to its use in confirmatory clinical trials.
The B-type Raf kinase (BRAF) in the mitogen-activated 
protein signaling pathway plays a key role in thyroid cancer. 
One common mutation occurs in about 29%–66% of papil-
lary thyroid cancers.15 Sorafenib is a multi-tyrosine kinase 
inhibitor whose targets include BRAF and VEGFR 1 and 2 
and has been studied in patients with advanced papillary 
thyroid cancer. Sorafenib activity was studied using immu-
nohistochemistry (IHC) for pERK, pAKT, and pVEGFR-2. 
BRAF mutation status was determined by DNA sequencing.16 
Of the first 15 patients treated, five patients achieved a partial 
response, three had stable disease, two progressed, and three 
patients with stable disease withdrew due to toxicity. Target 
lesions decreased on average 31%. Eight of 10 PET scans 
showed decreased activity at four weeks. IHC on tissue from 
two patients showed 50% decrease in pERK (downstream 
of VEGFR2 and BRAF) and 30% decrease in pAKT (down-
stream of VEGFR2). In tissue from a patient at 17 months on 
sorafenib, the decrease in pERK and pAKT appeared to be 
the same or reversed, suggesting compensatory changes in 
these pathways in resistant but stable disease. In conclusion, 
this study showed the early clinical and biologic activity of 
sorafenib in patients with mPTC and the targets of early 
suppression. Importantly, it also revealed compensatory 
changes in target molecules in cells resistant to therapy. 
These cells are the likely source of tumor resistance that has 
been seen to develop to other similar targeted agents.16 When 
patients with all types of thyroid cancer were treated with 
this agent, the results were equally impressive although the 
majority of cases had either follicular or papillary subtypes. 
Thirty patients were treated with a response rate of 23% and 
a stable disease rate of 53%. The median progression-free 
survival was 79 weeks.6 Phase II studies are currently still 
enrolling patients with other subtypes of thyroid cancer 
using this agent.
Targeted therapy with agents similar to the ones mentioned 
above appear to be useful in metastatic thyroid cancer treatment. 
Axitinib is a multitargeted agent against the VEGF receptors 
1, 2, and 3 and will be evaluated further in this paper.
Outcomes achieved in clinical 
development
Axitinib is one of a number of new targeted therapies being 
evaluated in the treatment of many cancers. It inhibits Core Evidence 2009:4 46
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the VEGF receptors at subnanomolar concentrations and 
also inhibits PDGFR-beta and c-Kit in low nanomolar 
concentrations. In a phase I trial designed not only to find 
the maximum tolerated dose, but also to look at the effect 
of food on pharmacokinetics, the planned starting dose 
of 30 mg twice daily was found to be too toxic.17 A dose 
de-escalation scheme determined the recommended dose for 
phase II trials to be 5 mg twice daily. Not surprisingly, 
the effect of food was found to decrease both the rate and 
extent of absorption and there was a median increase of 49% 
in the plasma exposures of the fasted compared with fed 
state. In the presence of a proton pump inhibitor, rabeprazole, 
the rate but not the extent of absorption was decreased, and 
so the concurrent use of this group of medications was felt to 
be not clinically significant. Twelve-hour urinary collections 
obtained on days 1 and 29, demonstrated that less than 1% 
of the administered dose appeared as unchanged drug in the 
urine regardless of dose, indicating that the majority of drug 
elimination was through systemic metabolism. The primary 
dose limiting toxicity was hypertension. This appeared to be 
dose-related and was controlled easily with antihypertensive 
medications. However, it was occasionally severe, and in the 
first cohort at a dose of 30 mg before hypertension guidelines 
were established, two patients suffered seizures although they 
recovered without sequelae. In the 14 patients treated at the 
recommended phase II dose, six developed hypertension, 
but it was not dose-limiting and was controlled by standard 
antihypertensive medications. Interestingly, no shifts in 
renin, angiotensin II, or aldosterone were seen, suggesting 
that axitinib-induced hypertension is not mediated by this 
pathway. One patient who had thyroid cancer had a reduction 
of tumor burden, but did not meet the RECIST criteria for 
a response.17
Based on these encouraging data, a phase II trial was per-
formed using axitinib given at a dose of 5 mg twice daily in 
patients with all types of aggressive incurable thyroid cancer.5 
Patients with hemoptysis and uncontrolled hypertension were 
excluded from this study. In total, 60 patients were enrolled, 30 
with papillary, 15 with follicular, and 11 with medullary cancer. 
A partial response was noted in 18 patients giving an overall 
response rate of 30%. Stable disease was reported in another 
23 (38%) and four patients (7%) had progressive disease as 
their best response. With a median follow up of 16.6 months, 
the median progression-free survival is 18.1 months which 
correlates well with the other small molecule studies men-
tioned above. The results were even more impressive as 
most of the patients enrolled were men and had metastatic 
disease, both poor prognostic factors. The most common 
adverse effects were fatigue, diarrhea, nausea, anorexia, and 
hypertension. Of these, hypertension was the most common 
grade 3 side effect, occurring in 12% of patients.
The effect of axitinib on soluble proteins as exploratory 
pharmacodynamic markers was also studied. Treatment with 
axitinib led to a 2.8-fold increase in mean VEGF concentra-
tions that generally reached a plateau by week 12. In contrast, 
there was a 32% decrease in mean sVEGFR-2 concentra-
tions, 35% decrease in mean sVEGFR-3 concentrations, 
and 13% decrease in mean sKIT concentrations in blood by 
week 12 compared with baseline. The decrease in sVEGFR 
reached a plateau within the first 12 weeks of treatment and 
was sustained for the duration of therapy in most patients. 
Given the paucity of patients with progressive disease, it was 
not possible to make a definitive assessment of the potential 
correlation of changes in sVEGFR-2 or sVEGFR-3 with 
objective response. However, these data demonstrate the 
selectivity of axitinib for modulating soluble VEGFRs versus 
sKIT in patients with thyroid cancer.
Calcitonin and thyroglobulin were both measured in 
subsets of patients in this study. Calcitonin was measured in 
seven patients with medullary thyroid cancer: two patients 
with progressive disease, three patients with stable disease, 
and two patients with partial response. Patients with progres-
sive disease did not have a change in calcitonin concentra-
tions; those with partial response had a marked decrease in 
calcitonin concentrations and patients with stable disease 
had a slight decrease in calcitonin.
Thyroglobulin was measured in two patients with pro-
gressive disease, 11 patients with stable disease, and eight 
patients with partial response. The preliminary assessment 
demonstrates that most patients, regardless of their clinical 
response to therapy, had initial decreases in thyroglobulin. 
However, because of the small number of patients with 
progressive disease in this trial, no definitive conclusions 
could be made for either calcitonin or thyroglobulin with 
regard to their utility as potential biomarkers of response 
to axitinib.5
For the most resistant thyroid cancers, monotherapy 
with axitinib may not be sufficient to control the disease. 
Chemotherapy has been used with some success in earlier 
thyroid cancer studies and therefore a combination of axitinib 
chemotherapy may represent another possible treatment 
option. Although these combinations have not been tested 
in the setting of thyroid cancer, they have been evaluated in 
other diseases. In two phase I studies reported at the 2008 
ESMO meeting, axitinib was combined with a variety of 
chemotherapy regimens including FOLFOX and FOLFIRI in Core Evidence 2009:4 47
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gastrointestinal malignancies and taxane-, capecitabine-, or 
gemcitabine-based treatments in a variety of solid malignan-
cies. In both studies, the pharmacokinetics were not affected 
by the addition of chemotherapy and the toxicities were not 
increased.18,19 More involved studies have also explored 
axitinib chemotherapy combinations with other new agents 
including a PDGFR inhibitor CP-868,596 combined with 
docetaxel and axitinib. Once again, the combination appeared 
safe, pharmacokinetic interactions were not observed, and 
antitumor effect was noted.20 Similar results were seen when 
axitinib was combined with FOLFOX and bevacizumab.21
In these days of exotic correlative markers, an intriguing 
retrospective analysis of the axitinib trials performed to 
date noted that patients who developed hypertension with a 
diastolic blood pressure of greater than 90 mmHg had a better 
survival than those whose did not become hypertensive. This 
appeared to be true for all tumor types, and in the case of 
thyroid cancer, the difference was 21.9 months survival for 
the nonhypertensive group compared with overall survival 
not reached for the hypertensive group of responders.22
Ongoing studies
Axitinib is currently being studied in an ongoing phase II trial 
in patients with metastatic thyroid cancers which are refrac-
tory to or ineligible for radioiodine therapy (NCT00176748). 
Another trial is currently enrolling patients who have 
131I-Refractory metastatic or unresectable locally-advanced 
papillary, follicular, or Hurthle-cell thyroid cancer who are 
also refractory to, or intolerant of, or have clinical contrain-
dication to, doxorubicin treatment (NCT00389441). Doxo-
rubicin remains the only US Food and Drug Administration 
(FDA)-approved treatment for iodine-refractory metastatic 
thyroid cancer and if this study meets its accrual expectations, 
it will be the largest study using the new small molecule 
inhibitors in this disease to date.23
Resource utilization
Thyroid cancers are rising in incidence faster than most other 
cancers, and therefore even though they remain a relatively 
uncommon disease today, in future their management could 
potentially become increasingly important to endocrinolo-
gists and medical oncologists. As the numbers of cancers 
increase, so do the numbers of patients who have aggressive 
refractory disease. Agents such as axitinib appear to have a 
toxicity profile that is much more favorable than the standard 
chemotherapy options that are currently available for use 
in this disease. Therefore, axitinib and similar compounds 
could potentially find themselves in increasing demand if 
the current trend of increasing numbers of thyroid cancer 
continues.
Patient group/population
Age and male gender appear to be the two main poor prognostic 
factors in patients with thyroid cancers and therefore this is 
probably the population who would gain the most benefit from 
aggressive treatment of this disease. Younger female patients 
can often have a long lifespan often in the presence of widely 
metastatic disease. However it is important to take each case 
individually and if the disease appears particularly aggressive, 
then axitinib should be considered as an option for treatment 
when it becomes available. Interestingly, axitinib may also 
have a place in the treatment of medullary and anaplastic 
thyroid cancers although the numbers of patients with these 
subtypes is too small to draw firm conclusions.
Clinical potential
Axitinib appears to be a very promising treatment for 
patients with aggressive iodine-refractory thyroid cancer. 
There are at least two other multitargeted kinase inhibitors 
which also have significant activity. It is difficult to compare 
these treatments as they have all only been tested in single 
arm phase II studies. They all appear to be well tolerated. 
Phase III studies will be needed to determine whether these 
agents are better than the current standard of care and if they 
should be approved for thyroid cancer treatment. Certainly 
the toxicity of these agents appears better than that of tradi-
tional chemotherapy, but many of the chemotherapy studies 
were performed before modern antiemetics and antibiotics 
were widely available.
There have been no quality of life studies with axitinib 
when used as a treatment for thyroid cancer. However, 
the QLQ-C30 health-related quality of life (HRQOL) 
questionnaire was incorporated into a study using axitinib 
in patients with renal cell cancer.24 The results were 
encouraging and appeared to show that there was an increase 
in survival with little or modest change from baseline levels 
in the majority of HRQOL domains and symptoms. The one 
exception was diarrhea, which appeared to get worse during 
treatment, although the average score did not change response 
categories to ‘a little’ until 120 weeks, 2.5 years after the 
start of treatment, and was still at that approximate level 
by 144 weeks. Thyroid cancer and renal cell cancer often 
share characteristics of a slowly progressive malignancy 
and therefore these results may be applicable when axitinib 
is used in the setting of thyroid cancer as well. However, 
this may be one of the biggest challenges for the widespread Core Evidence 2009:4
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use of these new small molecule inhibitors, as their initial 
cost is likely to be extremely high and many patients are 
asymptomatic even with widespread metastatic disease. Any 
benefit in survival should also be matched by an improvement 
in quality of life, as otherwise the economic burden of the 
treatment is likely to be prohibitive. However, the emergence 
of axitinib and its fellow compounds as viable options for 
treating refractory thyroid cancers represents a remarkable 
advance in treating these hitherto resistant tumors.
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